Previous 10 | Next 10 |
home / stock / cslly / cslly news
MAIDENHEAD, England , October 19, 2018 /PRNewswire/ -- Seqirus, a global leader in influenza prevention, today announced that its cell-based quadrivalent influenza vaccine (QIVc) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the Europe...
General Overview of Pipeline Catalyst Biosciences ( CBIO ) is a clinical-stage biopharmaceutical company focused on developing hemostasis treatments. Since the company became public after a merger deal with Targacept, it is known that Catalyst has engineered three therapeutic candidates ...
SAN FRANCISCO , Oct. 3, 2018 /PRNewswire/ -- Seqirus, a global leader in influenza prevention, today announced data, to be presented at IDWeek 2018 on Saturday, October 6 , showing that higher levels of mismatch have consistently occurred with egg-derived influenza vaccine viruses compar...
SAN FRANCISCO , Oct. 3, 2018 /PRNewswire/ -- Seqirus, a global leader in influenza prevention, will present new healthcare and cost outcomes data for its MF59®-adjuvanted trivalent influenza vaccine (FLUAD) at IDWeek in San Francisco ( October 5-6 ). Results from five differen...
KING OF PRUSSIA, Pa. , Sept. 18, 2018 /PRNewswire/ -- Thomson Reuters has ranked global biotechnology leader CSL Limited one of the top 100 companies in its 2018 global Diversity and Inclusion Index. This achievement reflects CSL's promise to build a workplace culture where employees ha...
CAMBRIDGE, Mass. , Aug. 23, 2018 /PRNewswire/ -- Seqirus, a global leader in influenza vaccine innovation, today announced FDA approval of its next generation cell-based manufacturing process at Holly Springs, North Carolina. The approval will enable Seqirus to more than double curr...
KING OF PRUSSIA, Pa. , Aug. 23, 2018 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced that IDELVION ® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rFIX-FP)], its novel, long-acting recombinant albumin fusion protein for treating hemophi...
The following slide deck was published by CSL Ltd. ADR in conjunction with their 2018 Q4 earnings Read more ...
MUNICH , July 26, 2018 /PRNewswire/ -- The Global Initiative on Sharing All Influenza Data (GISAID), a non-profit organization and public-private partnership dedicated to strengthening the world's defense against deadly influenza threats, today welcomed a €250,000 donation ...
KING OF PRUSSIA, Pa. , July 20, 2018 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced that it will support the presentation of 14 scientific posters at the 2018 annual meeting of the Peripheral Nerve Society (PNS) . Most notably, neuromuscular med...
News, Short Squeeze, Breakout and More Instantly...
CSL Ltd ADR Company Name:
CSLLY Stock Symbol:
OTCMKTS Market:
Recently Published Real-World Evidence Study Shows Effectiveness of Cell-Based Quadrivalent Influenza Vaccine Over Three Seasons PR Newswire A real-world evidence (RWE) study recently published in Open Forum Infectious Diseases (OFID) examined three consecutive U.S. flu seas...
PHILADELPHIA, April 30, 2024 (GLOBE NEWSWIRE) -- The Mark Cuban Foundation, in partnership with CSL, is bringing the only artificial intelligenc...
PHILADELPHIA, April 30, 2024 (GLOBE NEWSWIRE) -- The Mark Cuban Foundation, in partnership with CSL, is bringing the only artificial intelligence (AI) camp of its kind, free of charge, to high school students in Philadelphia. With a custom and highly-relevant curriculum focused on teaching studen...